What’s in Recro Pharma, Inc. (REPH) After Today’s Significant Increase?

March 14, 2018 - By Migdalia James

Investors sentiment decreased to 1.65 in Q3 2017. Its down 0.56, from 2.21 in 2017Q2. It fall, as 7 investors sold Recro Pharma, Inc. shares while 10 reduced holdings. 5 funds opened positions while 23 raised stakes. 9.63 million shares or 4.72% less from 10.10 million shares in 2017Q2 were reported.
Rhumbline Advisers stated it has 0% in Recro Pharma, Inc. (NASDAQ:REPH). Essex Invest Co Limited reported 93,199 shares stake. Janney Montgomery Scott Limited accumulated 0% or 16,485 shares. Geode Mgmt Ltd Company stated it has 0% in Recro Pharma, Inc. (NASDAQ:REPH). 167,637 were accumulated by Cadence Capital Mgmt Limited Liability Corporation. Kingdon Capital Management has invested 0.15% in Recro Pharma, Inc. (NASDAQ:REPH). Natl Bank Of Montreal Can accumulated 4,328 shares or 0% of the stock. Retail Bank Of Mellon Corporation reported 52,391 shares. Bb&T Corporation invested in 0.01% or 50,000 shares. Panagora Asset Management Incorporated holds 0% of its portfolio in Recro Pharma, Inc. (NASDAQ:REPH) for 8,144 shares. Manufacturers Life Ins The holds 140 shares. Granite Point Capital Mgmt L P owns 0.07% invested in Recro Pharma, Inc. (NASDAQ:REPH) for 38,000 shares. Vanguard Group Inc reported 666,252 shares. 25,000 are held by Rothschild Il. State Common Retirement Fund has 1,800 shares.

Since December 12, 2017, it had 0 insider purchases, and 5 selling transactions for $1.43 million activity. Another trade for 4,732 shares valued at $41,822 was made by SCP Vitalife Partners II LP on Thursday, January 4. 1,579 shares valued at $13,956 were sold by SCP Vitalife Partners (Israel) II – L.P. on Thursday, January 4.

The stock of Recro Pharma, Inc. (NASDAQ:REPH) is a huge mover today! The stock increased 8.19% or $0.85 during the last trading session, reaching $11.23. About 581,041 shares traded or 221.32% up from the average. Recro Pharma, Inc. (NASDAQ:REPH) has risen 26.61% since March 14, 2017 and is uptrending. It has outperformed by 9.91% the S&P500.
The move comes after 6 months positive chart setup for the $215.13 million company. It was reported on Mar, 14 by Barchart.com. We have $12.02 PT which if reached, will make NASDAQ:REPH worth $15.06 million more.

Analysts await Recro Pharma, Inc. (NASDAQ:REPH) to report earnings on May, 10. They expect $-0.68 earnings per share, down 61.90 % or $0.26 from last year’s $-0.42 per share. After $-0.63 actual earnings per share reported by Recro Pharma, Inc. for the previous quarter, Wall Street now forecasts 7.94 % negative EPS growth.

Recro Pharma, Inc. (NASDAQ:REPH) Ratings Coverage

Among 9 analysts covering Recro Pharma (NASDAQ:REPH), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Recro Pharma had 16 analyst reports since August 25, 2015 according to SRatingsIntel. The firm has “Buy” rating by Piper Jaffray given on Tuesday, July 25. As per Friday, September 16, the company rating was initiated by TH Capital. The rating was initiated by Oppenheimer with “Buy” on Tuesday, February 13. The stock has “Buy” rating by Roth Capital on Friday, September 16. The firm earned “Buy” rating on Monday, November 14 by Aegis Capital. The stock of Recro Pharma, Inc. (NASDAQ:REPH) earned “Buy” rating by H.C. Wainwright on Tuesday, November 24. On Tuesday, August 25 the stock rating was upgraded by Zacks to “Hold”. The rating was maintained by Piper Jaffray on Wednesday, February 28 with “Buy”. The rating was initiated by Brean Capital with “Buy” on Monday, October 3. The stock of Recro Pharma, Inc. (NASDAQ:REPH) has “Buy” rating given on Thursday, July 20 by Roth Capital.

More important recent Recro Pharma, Inc. (NASDAQ:REPH) news were published by: Globenewswire.com which released: “Recro Pharma Reports Year End 2017 Financial Results” on February 27, 2018, also Globenewswire.com published article titled: “Recro Pharma Announces Commercial Team Additions”, Globenewswire.com published: “Recro Pharma to Present at Upcoming Investor Conferences” on March 06, 2018. More interesting news about Recro Pharma, Inc. (NASDAQ:REPH) was released by: Globenewswire.com and their article: “Recro Pharma Announces Publication of Supportive Phase II IV Meloxicam …” with publication date: February 20, 2018.

Recro Pharma, Inc., a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company has market cap of $215.13 million. The Company’s lead product candidate includes injectable meloxicam, which completed pivotal Phase III clinical trials for the treatment of post-operative pain. It currently has negative earnings. The firm also provides Dex-IN, an intranasal formulation of dexmedetomidine that is in development stage for treating post-operative pain and peri-procedural pain; and Fadolmidine, alpha-2 agonist product for use in treating neuropathic pain.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.